Headlines about Seattle Genetics (NASDAQ:SGEN) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seattle Genetics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.5376369658202 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of brokerages recently issued reports on SGEN. BidaskClub raised Seattle Genetics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. ValuEngine raised Seattle Genetics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. TheStreet upgraded Seattle Genetics from a “d+” rating to a “c-” rating in a research note on Thursday, June 28th. Needham & Company LLC raised their price target on Seattle Genetics from $74.00 to $79.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Finally, Zacks Investment Research upgraded Seattle Genetics from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research note on Tuesday, July 3rd. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $70.93.

SGEN stock opened at $74.45 on Tuesday. The company has a market capitalization of $11.64 billion, a price-to-earnings ratio of -84.60 and a beta of 1.70. Seattle Genetics has a twelve month low of $45.31 and a twelve month high of $74.87.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, July 26th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.81. The firm had revenue of $170.20 million during the quarter, compared to the consensus estimate of $141.07 million. Seattle Genetics had a negative return on equity of 21.01% and a negative net margin of 7.75%. The business’s revenue was up 57.3% compared to the same quarter last year. During the same period last year, the company earned ($0.39) earnings per share. equities research analysts predict that Seattle Genetics will post -1.15 EPS for the current year.

In other news, insider Vaughn B. Himes sold 5,000 shares of Seattle Genetics stock in a transaction that occurred on Thursday, May 31st. The stock was sold at an average price of $58.47, for a total transaction of $292,350.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Clay B. Siegall sold 18,832 shares of Seattle Genetics stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $65.12, for a total value of $1,226,339.84. The disclosure for this sale can be found here. Insiders have sold a total of 80,949 shares of company stock valued at $5,532,794 over the last quarter. 33.80% of the stock is currently owned by corporate insiders.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Featured Article: Diversification For Individual Investors

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.